A citation-based method for searching scientific literature

Iciar Aviles-Olmos, Patricia Limousin, Andrew Lees, Thomas Foltynie. Brain 2013
Times Cited: 188







List of co-cited articles
1055 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
Dilan Athauda, Kate Maclagan, Simon S Skene, Martha Bajwa-Joseph, Dawn Letchford, Kashfia Chowdhury, Steve Hibbert, Natalia Budnik, Luca Zampedri, John Dickson,[...]. Lancet 2017
342
33


Exenatide and the treatment of patients with Parkinson's disease.
Iciar Aviles-Olmos, John Dickson, Zinovia Kefalopoulou, Atbin Djamshidian, Peter Ell, Therese Soderlund, Peter Whitton, Richard Wyse, Tom Isaacs, Andrew Lees,[...]. J Clin Invest 2013
281
23

Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease.
Iciar Aviles-Olmos, John Dickson, Zinovia Kefalopoulou, Atbin Djamshidian, Joshua Kahan, Peter Ell, Peter Whitton, Richard Wyse, Tom Isaacs, Andrew Lees,[...]. J Parkinsons Dis 2014
163
21

Type 2 diabetes and the risk of Parkinson's disease.
Gang Hu, Pekka Jousilahti, Siamak Bidel, Riitta Antikainen, Jaakko Tuomilehto. Diabetes Care 2007
290
21

GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism.
Yazhou Li, TracyAnn Perry, Mark S Kindy, Brandon K Harvey, David Tweedie, Harold W Holloway, Kathleen Powers, Hui Shen, Josephine M Egan, Kumar Sambamurti,[...]. Proc Natl Acad Sci U S A 2009
405
20

Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease.
Göran Bertilsson, Cesare Patrone, Olof Zachrisson, Annica Andersson, Karin Dannaeus, Jessica Heidrich, Jarkko Kortesmaa, Alex Mercer, Elisabet Nielsen, Harriet Rönnholm,[...]. J Neurosci Res 2008
241
19

Diabetes and risk of Parkinson's disease.
Qun Xu, Yikyung Park, Xuemei Huang, Albert Hollenbeck, Aaron Blair, Arthur Schatzkin, Honglei Chen. Diabetes Care 2011
166
18

Shared dysregulated pathways lead to Parkinson's disease and diabetes.
Jose A Santiago, Judith A Potashkin. Trends Mol Med 2013
138
17


Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson's disease occurring with Type 2 diabetes in a Taiwanese population cohort.
Mark L Wahlqvist, Meei-Shyuan Lee, Chih-Cheng Hsu, Shao-Yuan Chuang, Jiunn-Tay Lee, Hsin-Ni Tsai. Parkinsonism Relat Disord 2012
149
16

Parkinson's disease.
Lorraine V Kalia, Anthony E Lang. Lancet 2015
16

Insulin resistance impairs nigrostriatal dopamine function.
J K Morris, G L Bomhoff, B K Gorres, V A Davis, J Kim, P-P Lee, W M Brooks, G A Gerhardt, P C Geiger, J A Stanford. Exp Neurol 2011
93
16

Association between diabetes and subsequent Parkinson disease: A record-linkage cohort study.
Eduardo De Pablo-Fernandez, Raph Goldacre, Julia Pakpoor, Alastair J Noyce, Thomas T Warner. Neurology 2018
111
15

An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Aβ oligomers.
Theresa R Bomfim, Leticia Forny-Germano, Luciana B Sathler, Jordano Brito-Moreira, Jean-Christophe Houzel, Helena Decker, Michael A Silverman, Hala Kazi, Helen M Melo, Paula L McClean,[...]. J Clin Invest 2012
579
13


Diabetes and risk of Parkinson's disease: a systematic review and meta-analysis.
Emanuele Cereda, Michela Barichella, Carlo Pedrolli, Catherine Klersy, Erica Cassani, Riccardo Caccialanza, Gianni Pezzoli. Diabetes Care 2011
138
13


Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease.
Alexander Harkavyi, Amjad Abuirmeileh, Rebecca Lever, Ann E Kingsbury, Christopher S Biggs, Peter S Whitton. J Neuroinflammation 2008
191
13

Diabetes and the risk of developing Parkinson's disease in Denmark.
Eva Schernhammer, Johnni Hansen, Kathrine Rugbjerg, Lene Wermuth, Beate Ritz. Diabetes Care 2011
119
13

Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline.
Konrad Talbot, Hoau-Yan Wang, Hala Kazi, Li-Ying Han, Kalindi P Bakshi, Andres Stucky, Robert L Fuino, Krista R Kawaguchi, Andrew J Samoyedny, Robert S Wilson,[...]. J Clin Invest 2012
13

Obesity, diabetes, and risk of Parkinson's disease.
Natalia Palacios, Xiang Gao, Marjorie L McCullough, Eric J Jacobs, Alpa V Patel, Tinisha Mayo, Michael A Schwarzschild, Alberto Ascherio. Mov Disord 2011
100
13

Diabetes mellitus and Parkinson disease.
Gennaro Pagano, Sotirios Polychronis, Heather Wilson, Beniamino Giordano, Nicola Ferrara, Flavia Niccolini, Marios Politis. Neurology 2018
93
13

Dementia is associated with insulin resistance in patients with Parkinson's disease.
Domenico Bosco, Massimiliano Plastino, Dario Cristiano, Carmela Colica, Caterina Ermio, Matteo De Bartolo, Pasquale Mungari, Giulia Fonte, Domenico Consoli, Arturo Consoli,[...]. J Neurol Sci 2012
81
14


Insulin resistance and exendin-4 treatment for multiple system atrophy.
Fares Bassil, Marie-Hélène Canron, Anne Vital, Erwan Bezard, Yazhou Li, Nigel H Greig, Seema Gulyani, Dimitrios Kapogiannis, Pierre-Olivier Fernagut, Wassilios G Meissner. Brain 2017
56
21


Diabetes is associated with postural instability and gait difficulty in Parkinson disease.
Vikas Kotagal, Roger L Albin, Martijn L T M Müller, Robert A Koeppe, Kirk A Frey, Nicolaas I Bohnen. Parkinsonism Relat Disord 2013
62
17

Glitazone Treatment and Incidence of Parkinson's Disease among People with Diabetes: A Retrospective Cohort Study.
Ruth Brauer, Krishnan Bhaskaran, Nishi Chaturvedi, David T Dexter, Liam Smeeth, Ian Douglas. PLoS Med 2015
82
13


Glucagon-like peptide-1 receptor is involved in learning and neuroprotection.
Matthew J During, Lei Cao, David S Zuzga, Jeremy S Francis, Helen L Fitzsimons, Xiangyang Jiao, Ross J Bland, Matthias Klugmann, William A Banks, Daniel J Drucker,[...]. Nat Med 2003
590
11

Pharmacology, physiology, and mechanisms of incretin hormone action.
Jonathan E Campbell, Daniel J Drucker. Cell Metab 2013
817
11

A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson's disease by increasing expression of BNDF.
Chenhui Ji, Guo-Fang Xue, Cao Lijun, Peng Feng, Dongfang Li, Lin Li, Guanglai Li, Christian Hölscher. Brain Res 2016
62
17


Clinical features of Parkinson disease when onset of diabetes came first: A case-control study.
E Cereda, M Barichella, E Cassani, R Caccialanza, G Pezzoli. Neurology 2012
91
10

The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease.
Paula L McClean, Vadivel Parthsarathy, Emilie Faivre, Christian Hölscher. J Neurosci 2011
469
10

Risk of Parkinson disease onset in patients with diabetes: a 9-year population-based cohort study with age and sex stratifications.
Yu Sun, Ya-Hui Chang, Hua-Fen Chen, Ying-Hwa Su, Hui-Fang Su, Chung-Yi Li. Diabetes Care 2012
124
10

Loss of insulin receptor immunoreactivity from the substantia nigra pars compacta neurons in Parkinson's disease.
I Moroo, T Yamada, H Makino, I Tooyama, P L McGeer, E G McGeer, K Hirayama. Acta Neuropathol 1994
116
10


A novel GLP-1/GIP dual agonist is more effective than liraglutide in reducing inflammation and enhancing GDNF release in the MPTP mouse model of Parkinson's disease.
Ziyue Yuan, Dongfang Li, Peng Feng, Guofang Xue, Chenhui Ji, Guanglai Li, Christian Hölscher. Eur J Pharmacol 2017
53
18

Neuroprotective effects of a GIP analogue in the MPTP Parkinson's disease mouse model.
Yanwei Li, WeiZhen Liu, Lin Li, Christian Hölscher. Neuropharmacology 2016
51
19



Parkinson disease.
Werner Poewe, Klaus Seppi, Caroline M Tanner, Glenda M Halliday, Patrik Brundin, Jens Volkmann, Anette-Eleonore Schrag, Anthony E Lang. Nat Rev Dis Primers 2017
10

Cross-talk between amyloidogenic proteins in type-2 diabetes and Parkinson's disease.
Istvan Horvath, Pernilla Wittung-Stafshede. Proc Natl Acad Sci U S A 2016
82
12

Biology of incretins: GLP-1 and GIP.
Laurie L Baggio, Daniel J Drucker. Gastroenterology 2007
9

Metabolic inflammation exacerbates dopaminergic neuronal degeneration in response to acute MPTP challenge in type 2 diabetes mice.
Ling Wang, Ying-Qi Zhai, Li-Li Xu, Chen Qiao, Xiu-Lan Sun, Jian-Hua Ding, Ming Lu, Gang Hu. Exp Neurol 2014
63
14

Entry of exendin-4 into brain is rapid but may be limited at high doses.
A J Kastin, V Akerstrom. Int J Obes Relat Metab Disord 2003
255
9

Neuroendocrine abnormalities in Parkinson's disease.
Eduardo De Pablo-Fernández, David P Breen, Pierre M Bouloux, Roger A Barker, Thomas Foltynie, Thomas T Warner. J Neurol Neurosurg Psychiatry 2017
56
16

Association between Parkinson's disease and diabetes: Data from NEDICES study.
E De Pablo-Fernandez, F Sierra-Hidalgo, J Benito-León, F Bermejo-Pareja. Acta Neurol Scand 2017
37
24


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.